glucagon suppression, lowering hepatic glucose output Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses) Adiposity/Energy Intake : Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure Biological Activity Potent GLP-1 receptor agonist Enhances insulin secretion (glucose-dependent) Suppresses glucagon secretion Reduces appetite and caloric intake Produces significant, sustained body weight loss Improves cardiometabolic risk factors (glycemia, blood pressure, lipids) Storage Refrigerate once reconstituted
At first, prescribing starts from 3 mg
Off-label use for women who have gained 10-20 lbs during menopause, or for people at a normal body weight who want it for the brain/heart/kidney protective effects, is a much harder situation
Your review * Not too sure, its been two weeks
Table of Contents How GLP-1 Medications Affect Appetite and Food Choices Nutritional Considerations When Taking GLP-1 Treatments Choosing Fast Food Options While on GLP-1 Therapy Managing Portion Sizes and Satiety on GLP-1 Medications Common Side Effects and Food Tolerance on GLP-1 Drugs Scientific References Frequently Asked Questions How GLP-1 Medications Affect Appetite and Food Choices Glucagon-like peptide-1 (GLP-1) receptor agonists have specific licensed indications in the UK
It is unknown whether the pharmacokinetic profile would allow a once daily administration
